Mechanisms of Anaphylaxis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03182491

Acronym

ANAMEK

Enrollment

Registered

2017-06-09

Start date

2017-04-28

Completion date

2026-10-01

Last updated

2022-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy, Anaphylaxis, Febrile Transfusion Reaction, Transfusion Reaction

Keywords

Platelet activating factor, Basophil activation test, Anaphylatoxins

Brief summary

The purpose of this study is to explore different mechanisms for anaphylaxis and find novel biomarkers for this hypersensitivity syndrome. The study participants are patients with anaphylaxis, patients with mild allergic reactions, and patients with febrile transfusion reactions. The investigators will also include a group of healthy controls.

Interventions

DIAGNOSTIC_TESTBiomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)

Analysis of biomarkers and basophil activation test

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to 120 Years

Healthy volunteers

Yes

Inclusion criteria

According to the specific cohort: 1. Diagnosis of anaphylaxis 2. Mild allergic reaction 3. Febrile transfusion reaction 4. Healthy, no known allergic disease

Exclusion criteria

Suspicion or diagnosed sepsis Children

Design outcomes

Primary

Measure	Time frame	Description
Clarify mechanisms for anaphylaxis and establish biomarkers for this syndrome	2 days	Immunological/nonimmunological mechanism

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026